相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Roy S. Herbst et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer
Yuji Shibata et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
Masatoshi Kudo
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy
Fatemeh K. Dermani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer
Joseph A. Pinto et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment
Hong Sheng Cheng et al.
MOLECULAR CANCER (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S. Herbst et al.
LANCET ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Xiaolei Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Anti-Angiogenics: Their Value in Lung Cancer Therapy
Melanie Janning et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Neuropilin-1 expression is associated with lymph node metastasis in breast cancer tissues
Mahnaz Seifi-Alan et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
Improving immune-vascular crosstalk for cancer immunotherapy
Yuhui Huang et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI
Lei Deng et al.
NEOPLASIA (2017)
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression
Heather J Dalton et al.
CLINICAL CANCER RESEARCH (2017)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells' Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer
Filippos Koinis et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Nasser H. Hanna et al.
LUNG CANCER (2016)
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E. Peterson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
E. C. Martino et al.
CELL DEATH DISCOVERY (2016)
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner
Kien Pham et al.
CANCER LETTERS (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model
Stephanie Du Four et al.
ONCOIMMUNOLOGY (2015)
Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication
Oana Draghiciu et al.
ONCOIMMUNOLOGY (2015)
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function
Annkristin Heine et al.
PLOS ONE (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Alexander Doemling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Cancer Treatment and Survivorship Statistics, 2014
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Gregory T. Motz et al.
NATURE MEDICINE (2014)
Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models
Leilei Tao et al.
MEDICAL ONCOLOGY (2014)
Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes
Konrad Gabrusiewicz et al.
ONCOTARGET (2014)
Does the immune system naturally protect against cancer?
Alexandre Corthay
FRONTIERS IN IMMUNOLOGY (2014)
Control of the immune response by pro-angiogenic factors
Thibault Voron et al.
FRONTIERS IN ONCOLOGY (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Yuhui Huang et al.
CANCER RESEARCH (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy
Margaret K. Callahan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models
Shujing Shi et al.
PLOS ONE (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Wiebke Hansen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Pipsa Saharinen et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
Kiavash Movahedi et al.
CANCER RESEARCH (2010)
VEGFR2 is selectively expressed by FOXP3(high) CD4(+) Treg
Hiroyuki Suzuki et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
M. Manzoni et al.
ONCOLOGY (2010)
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
C. Alfaro et al.
BRITISH JOURNAL OF CANCER (2009)
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
Junko Ozao-Choy et al.
CANCER RESEARCH (2009)
Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Massimiliano Mazzone et al.
CELL (2009)
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
Jennifer S. Ko et al.
CLINICAL CANCER RESEARCH (2009)
Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
Christina L. Roland et al.
PLOS ONE (2009)
Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients
James H. Finke et al.
CLINICAL CANCER RESEARCH (2008)
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis
Christian Stockmann et al.
NATURE (2008)
Drug resistance and the solid tumor microenvironment
Olivier Tredan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hernatopoiesis associated with elevated levels of VEGF
Yuhui Huang et al.
BLOOD (2007)
Tregs and rethinking cancer immunotherapy
Tyler J. Curiel
JOURNAL OF CLINICAL INVESTIGATION (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy
Betty Li et al.
CLINICAL CANCER RESEARCH (2006)
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
B Huang et al.
CANCER RESEARCH (2006)
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
DJ Hicklin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Y Nefedova et al.
JOURNAL OF IMMUNOLOGY (2004)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
IFN-γ-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-γ
GL Beatty et al.
JOURNAL OF IMMUNOLOGY (2001)
分享论文
